# Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

> **NCT07149090** · PHASE1,PHASE2 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 61 (estimated)

## Conditions studied

- STOMACH NEOPLASM
- Gastric Cancer
- Gastric Cancer Adenocarcinoma Metastatic

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07149090
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07149090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07149090, "Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07149090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*